Pharma valuation roundup: year-end scorecard

A blog post reviewing pharmaceutical company valuation shifts at year-end, citing company-specific developments and broader market dynamics. No radiology-specific findings or imaging data reported.

• This is a general pharma finance commentary piece with no radiology, imaging, or diagnostic content.
• No clinical trial data, device clearances, or practice-relevant findings for radiologists are present in the source snippet.
• Relevance to RadPigeon readership is negligible; included for completeness only.

RadPigeon summaries are original and for information only. They are not clinical advice.